Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

Por Alok A. Khorana, Mairéad G. McNamara, Ajay K. Kakkar, Michael B. Streiff, Hanno Riess, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Gerald A. Soff
Publicado em 2020-04-01

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

Por Jan Beyer-Westendorf, A. John Camm, Keith A. A. Fox, Jean-Yves Le Heuzey, Sylvia Haas, Alexander G. G. Turpie, Saverio Virdone, Ajay K. Kakkar, for the RIVER Registry Investigators
Publicado em 2019-04-01

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

Por Sylvia Haas, Hugo Ten Cate, Gabriele Accetta, Pantep Angchaisuksiri, Jean-Pierre Bassand, A John Camm, Ramon Corbalan, Harald Darius, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Lorenzo G Mantovani, Frank Misselwitz, Karen Pieper, Sebastian M Schellong, Janina Stepinska, Alexander G G Turpie, Martin van Eickels, Ajay K Kakkar, GARFIELD-AF Investigators
Publicado em 2016-01-01